Showing 7991-8000 of 18164 results for "".
Living Donors
https://reachmd.com/programs/clinicians-roundtable/living-donors/1675/Has a patient asked you yet, your medical opinion regarding their decision to become a living donor? The number of living liver donors is growing each year. The ability to give the gift of life to another is appealing to many but what are the costs? What are the risks? What are the health requirBiomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
https://reachmd.com/programs/cme/biomarker-directed-approaches-for-frontline-treatment-of-advanced-gastricgej-cancers-the-evidence/29846/Watch our experts discuss guidelines-driven treatment selection for GI cancers and the data supporting these approaches.Patient-Centric Care in Rheumatic Disease: Alternative Approaches to Managing Pain
https://reachmd.com/programs/living-rheum/patient-centric-care-in-rheumatic-disease-alternative-approaches-to-managing-pain/30078/Explore the future of pain management in rheumatic diseases.What Are the Latest Advances in Lupus Care?
https://reachmd.com/programs/conference-coverage/what-are-the-latest-advances-in-lupus-care/10308/Although nonrenal lupus patients face a variety of challenges, there’s fortunately been a lot of advances in care, as outlined by a guru in lupus.Data Equity in Action: Largest Real-World MS Analysis Confirms Fumarate Efficacy Across Racial Groups
https://reachmd.com/programs/neurofrontiers/Data-Equity-in-Action-Largest-Real-World-MS-Analysis-Confirms-Fumarate-Efficacy-Across-Racial-Groups/36351/mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
https://reachmd.com/programs/project-oncology/mcrpc-care-reducing-progression-risk-by-combining-enzalutamide-and-talazoparib/17801/Dive into the findings from the TALAPRO-2 trial, which examined a combination regimen for metastatic castration-resistant prostate cancer.Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
https://reachmd.com/programs/project-oncology/early-liquid-biopsy-in-advanced-lung-cancer-real-world-data-suggest-targeted-gains/39033/Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
https://reachmd.com/programs/heart-matters/current-and-emerging-treatments-for-transthyretin-amyloid-cardiomyopathy/36139/Treatment options for transthyretin amyloid cardiomyopathy have expanded significantly in recent years, moving from no approved therapies to multiple agents across distinct mechanistic classes. Join Dr. Ahmad Masri, Associate Professor of Medicine in the Division of Cardiovascular Medicine at OregonCost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
https://reachmd.com/programs/heart-matters/cost-effectiveness-of-universal-vs-selective-screening-for-attr-cm-in-hfpef-patients/32421/Hear about economic considerations in universal vs. selective screening for ATTR-CM in patients with heart failure with preserved ejection fraction.Diagnosing and Managing Psoriasis: What Primary Care Providers Need to Know
https://reachmd.com/programs/clinicians-roundtable/diagnosing-and-managing-psoriasis-what-primary-care-providers-need-to-know/32445/Learn how primary care providers can effectively diagnose, manage, and support patients with psoriasis.